(Q36260666)

13 August 2017

title

Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors (English)

1 reference

13 August 2017

Peyton Cramer

1

1 reference

13 August 2017

Robert S Bresalier

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2017

1 reference

Current gastroenterology reports

13 August 2017

published in

1 reference

13 August 2017

volume

19

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11894-017-0540-6

13 August 2017

exact match

0 references

cites work

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Biomarkers associated with checkpoint inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

IL-13Rα2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Ulcerative colitis or Crohn's disease? Pitfalls and problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Immunopathogenesis of IBD: current state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Acute and chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Anti-PD1-induced collagenous colitis in a melanoma patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Ipilimumab-induced acute severe colitis treated by infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

Infectious and malignant complications of TNF inhibitor therapy in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-017-0540-6

21 January 2018

1 reference

12 December 2020

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

1 reference

12 December 2020

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

1 reference

12 December 2020

Multiple vitamin status in Crohn's disease. Correlation with disease activity

1 reference

12 December 2020

Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance.

1 reference

12 December 2020

Pantothenic acid, coenzyme A, and human chronic ulcerative and granulomatous colitis

1 reference

12 December 2020

[Autoimmune hepatitis]

1 reference

12 December 2020

10.1007/S11894-017-0540-6

Identifiers

DOI

1 reference

13 August 2017

1 reference